Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) – Pipeline Review, H2 2017’, provides in depth analysis on Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Oncology under development targeting Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21)

The report reviews Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics and enlists all their major and minor projects

The report assesses Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC 2.7.11.21) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

Boehringer Ingelheim GmbH

Cyclacel Pharmaceuticals Inc

Marina Biotech Inc

Onconova Therapeutics Inc

Takeda Pharmaceutical Co Ltd

Trovagene Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC

2.7.11.21) - Overview 6

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC

2.7.11.21) - Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 12

Products under Development by Universities/Institutes 15

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC

2.7.11.21) - Therapeutics Assessment 17

Assessment by Mechanism of Action 17

Assessment by Route of Administration 18

Assessment by Molecule Type 20

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC

2.7.11.21) - Companies Involved in Therapeutics Development 22

Boehringer Ingelheim GmbH 22

Cyclacel Pharmaceuticals Inc 22

Marina Biotech Inc 23

Onconova Therapeutics Inc 23

Takeda Pharmaceutical Co Ltd 24

Trovagene Inc 24

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC

2.7.11.21) - Drug Profiles 26

CYC-140 - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

LS-008 - Drug Profile 28

Product Description 28

Mechanism Of Action 28

R&D Progress 28

M-400 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

PCM-075 - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

rigosertib sodium - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

Small Molecule to Inhibit PLK1 for Oncology - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Small Molecules to Inhibit PLK1 for Oncology - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Small Molecules to Inhibit PLK1 for Squamous Cell Carcinoma - Drug Profile 50

Product Description 50

Mechanism Of Action 50

R&D Progress 50

volasertib trihydrochloride - Drug Profile 51

Product Description 51

Mechanism Of Action 51

R&D Progress 51

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC

2.7.11.21) - Dormant Products 55

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC

2.7.11.21) - Discontinued Products 58

Serine/Threonine Protein Kinase PLK1 (Polo Like Kinase 1 or Serine/Threonine Protein Kinase 13 or PLK1 or EC

2.7.11.21) - Product Development Milestones 59

Featured News & Press Releases 59

Nov 01, 2017: Onconova Announces Two Presentations on Rigosertib in Myelodysplastic Syndromes at the ASH 2017 Annual Meeting 59

Oct 18, 2017: Trovagene's PLK1 Inhibitor (PCM-075) Demonstrates Synergy with Zytiga (abiraterone acetate) in Castration Resistant Prostate Cancer Tumor Cells 59

Oct 10, 2017: Initiation of Patient Enrollment in the Phase 1 Clinical Trial of Single-Agent Oral Rigosertib in Higher-Risk Myelodysplastic Syndromes 60

Oct 09, 2017: FDA Grants Orphan Drug Designation to Trovagenes PLK1 Inhibitor, PCM-075, for the Treatment of Acute Myeloid Leukemia (AML) 60

Oct 04, 2017: Onconova to Host Key Opinion Leader Meeting on Novel Approaches to the Diagnosis and Treatment of Pediatric RASopathies on Wednesday, October 11, in New York City 61

Aug 21, 2017: Trovagene's PLK1 Inhibitor PCM-075 Demonstrates Synergy with a HDAC Inhibitor in Non-Hodgkin Lymphoma Cell Lines 61

Aug 16, 2017: Trovagene's PLK1 Inhibitor PCM-075, in Preclinical AML Data, Significantly Enhances the Efficacy of a FLT3 inhibitor in Combination Therapy 62

Jul 27, 2017: Trovagene Announces FDA Approval of IND for Phase 1b/2 Trial of PCM-075 in Patients with Acute Myeloid Leukemia 62

Jul 25, 2017: Onconova Therapeutics Announces Establishment of Collaborative Research and Clinical Programs Evaluating Rigosertib in Pediatric “RASopathies” 63

Jul 25, 2017: Greater selectivity for PLK1, potency, oral bioavailability and short half-life underscore PCM-075s potential as safe and effective treatment for solid tumor and hematological malignancies 64

Jul 06, 2017: Trovagene Engages Leading CRO in AML to Conduct Phase 1b/2 Trial of PCM-075 64

Jun 29, 2017: Trovagene Announces Manufacturing Agreement with NerPharMa for Supply of PCM-075 for AML Trial 65

Jun 27, 2017: Trovagene Announces Submission of Investigational New Drug Application to Initiate Phase 1b/2 Clinical Trial of PCM-075 for Acute Myeloid Leukemia 65

Jun 26, 2017: Onconova Therapeutics Presents Rigosertib Data at the 22nd Congress of the European Hematology Association in Madrid 66

Jun 26, 2017: Trovagene Announces Expansion of Key Claims for its NPM1 Patent Portfolio for Acute Myeloid Leukemia 67

Appendix 69

Methodology 69

Coverage 69

Secondary Research 69

Primary Research 69

Expert Panel Validation 69

Contact Us 69

Disclaimer 70

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indications, H2 2017 9

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 11

Number of Products under Development by Companies, H2 2017 12

Products under Development by Companies, H2 2017 13

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 14

Number of Products under Investigation by Universities/Institutes, H2 2017 15

Products under Investigation by Universities/Institutes, H2 2017 16

Number of Products by Stage and Mechanism of Actions, H2 2017 17

Number of Products by Stage and Route of Administration, H2 2017 19

Number of Products by Stage and Molecule Type, H2 2017 21

Pipeline by Boehringer Ingelheim GmbH, H2 2017 22

Pipeline by Cyclacel Pharmaceuticals Inc, H2 2017 23

Pipeline by Marina Biotech Inc, H2 2017 23

Pipeline by Onconova Therapeutics Inc, H2 2017 24

Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 24

Pipeline by Trovagene Inc, H2 2017 25

Dormant Products, H2 2017 55

Dormant Products, H2 2017 (Contd..1), H2 2017 56

Dormant Products, H2 2017 (Contd..2), H2 2017 57

Discontinued Products, H2 2017 58

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Top 10 Indications, H2 2017 9

Number of Products by Stage and Mechanism of Actions, H2 2017 17

Number of Products by Routes of Administration, H2 2017 18

Number of Products by Stage and Routes of Administration, H2 2017 18

Number of Products by Molecule Types, H2 2017 20

Number of Products by Stage and Molecule Types, H2 2017 20

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports